Bortezomib-thalidomide-dexamethasone (VTD) is superior to bortezomib-cyclophosphamide-dexamethasone (VCD) as induction therapy prior to autologous stem cell transplantation in multiple myeloma
2015; Springer Nature; Volume: 29; Issue: 12 Linguagem: Inglês
10.1038/leu.2015.274
ISSN1476-5551
AutoresMichèle Cavo, Lucia Pantani, Annalisa Pezzi, MT Petrucci, Fabrizio Patriarca, Francesco Di Raimondo, G Marzocchi, Mónica Galli, Vittorio Montefusco, Elena Zamagni, Barbara Gamberi, Paola Tacchetti, Annamaria Brioli, Antonio Palumbo, Pieter Sonneveld,
Tópico(s)Peptidase Inhibition and Analysis
ResumoBortezomib-thalidomide-dexamethasone (VTD) is superior to bortezomib-cyclophosphamide-dexamethasone (VCD) as induction therapy prior to autologous stem cell transplantation in multiple myeloma
Referência(s)